Eliyahu Kalif - Teva Pharmaceutical Ex CFO
| TEV Stock | EUR 21.20 0.70 3.41% |
Insider
Eliyahu Kalif is Ex CFO of Teva Pharmaceutical Industries
| Age | 50 |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Aymeric Chatelier | Ipsen SA | 54 | |
| Torbjrn Hallberg | Swedish Orphan Biovitrum | 54 | |
| Paul Surdez | Catalent | N/A | |
| Pablo Mora | Swedish Orphan Biovitrum | 55 | |
| Haruhiko Hirate | Takeda Pharmaceutical | 66 | |
| Thomas Larsen | Swedish Orphan Biovitrum | 49 | |
| Julien Meissonnier | Catalent | N/A | |
| Ryuichi Kiyama | Shionogi Co | N/A | |
| Deepak MBA | Dr Reddys Laboratories | 48 | |
| William Price | Zoetis Inc | N/A | |
| Haruo Naito | Eisai Co | 76 | |
| Wetteny Joseph | Zoetis Inc | 51 | |
| Craig Marks | Ipsen SA | N/A | |
| Guido Oelkers | Swedish Orphan Biovitrum | 58 | |
| Yoshimasa Kyokawa | Shionogi Co | N/A | |
| Norimasa Takeda | Takeda Pharmaceutical | N/A | |
| Francois Garnier | Ipsen SA | 61 | |
| Christine Wesstrom | Swedish Orphan Biovitrum | 48 | |
| MS BTech | Dr Reddys Laboratories | 56 | |
| Dominique Bery | Ipsen SA | 52 | |
| Kohji Hanasaki | Shionogi Co | N/A | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eli Shani, Ex Portfolio | ||
| David Stark, Ex Officer | ||
| Mark Sabag, Ex Commercial | ||
| Eric Drape, Ex Operations | ||
| Sven Dethlefs, Ex Commercial | ||
| Kevin Mannix, VP Relations | ||
| Eliyahu Kalif, Ex CFO | ||
| Kathleen Veit, Global VP | ||
| Kare Schultz, CEO Pres | ||
| Amir Weiss, VP Officer |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.17 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 49.70 % | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.61 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.